News Releases
- September 13, 2022Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases
- September 8, 2022Annovis Bio's CEO Maria Maccecchini Issues Letter to Stockholders
- August 29, 2022Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer
- August 24, 2022Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease
- August 8, 2022Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update
- August 1, 2022Annovis Bio to Participate on Alzheimer's Association International Conference Panel
- July 14, 2022Annovis Bio to Present at the Alzheimer's Association International Conference
- July 7, 2022Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease
- June 9, 2022Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections
- December 14, 2021Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
- May 4, 2022Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update
- April 28, 2022Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging
- April 11, 2022Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease
Media Coverage
Events & Presentations
-
Annovis R&D Day Webcast View Webcast
-
Annovis Corporate Presentation - October 2023
-
AD-PD Conference - March 2022
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top